TRK-250 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Inhaled Dose, Safety, Tolerability, and Pharmacokinetic Study of TRK-250 in Subjects With Idiopathic Pulmonary Fibrosis
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs BNC 1021 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- Sponsors Toray Industries
- 16 Jan 2019 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 Status changed from planning to not yet recruiting.
- 27 Jul 2018 New trial record